Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptist Gallwitz

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
Handbook of Experimental Pharmacology|January 18, 2012
Anorexigenic effects of GLP-1 and its analoguesBaptist Gallwitz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptinBaptist Gallwitz
Frontiers in Endocrinology|October 31, 2022
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesityBaptist Gallwitz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|January 16, 2013
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesBaptist Gallwitz
Therapeutic Advances in Endocrinology and Metabolism|June 5, 2013
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factorsBaptist Gallwitz
Drugs of Today (Barcelona, Spain : 1998)|November 8, 2007
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetesBaptist Gallwitz
Endocrine Development|January 30, 2016
Novel Therapeutic Approaches in DiabetesBaptist Gallwitz
European Endocrinology|April 11, 2018
Cardiovascular Outcomes with Empagliflozin - News for Type 2 Diabetes TherapyBaptist Gallwitz
European Endocrinology|June 21, 2018
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World DataBaptist Gallwitz
European Endocrinology|June 7, 2018
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?Baptist Gallwitz
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
Handbook of Experimental Pharmacology|January 18, 2012
Anorexigenic effects of GLP-1 and its analoguesBaptist Gallwitz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptinBaptist Gallwitz
Frontiers in Endocrinology|October 31, 2022
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesityBaptist Gallwitz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|January 16, 2013
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesBaptist Gallwitz
Therapeutic Advances in Endocrinology and Metabolism|June 5, 2013
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factorsBaptist Gallwitz
Drugs of Today (Barcelona, Spain : 1998)|November 8, 2007
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetesBaptist Gallwitz
Endocrine Development|January 30, 2016
Novel Therapeutic Approaches in DiabetesBaptist Gallwitz
European Endocrinology|April 11, 2018
Cardiovascular Outcomes with Empagliflozin - News for Type 2 Diabetes TherapyBaptist Gallwitz
European Endocrinology|June 21, 2018
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World DataBaptist Gallwitz
European Endocrinology|June 7, 2018
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?Baptist Gallwitz
Pageof 13